ArticleScientific reports2025
Isolation and validation of antimalarial compounds from Phyllanthus emblica leaves for new antimalarial drug development.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Computational Identification of Triphala-Derived Sterol Compounds as Putative Agonists of the Human Takeda G Protein-Coupled Receptor (TGR5).International journal of molecular sciences · 2026Article
- Therapeutic potential ofRSC advances · 2025Review
- Study on the extraction, antioxidant and prebiotic activity of the polysaccharides from the fruits ofFrontiers in nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Natural products can serve as an alternative source of novel therapies that are required to address the problem of malarial infection resistance. Indian gooseberry (Phyllanthus emblica L.) leaves are often used in traditional medicine to treat fevers, but there isn't enough scientific proof that they contain antimalarial and effective phytochemicals. This study's primary goal was to investigate the antimalarial efficacy of P. emblica leaf ethyl acetate extract against Plasmodium falciparum (3D7) and its cytotoxicity against the HeLa cell line. The active compounds from P. emblica were isolated using a bioassay-guided fractionation of column chromatography technique, and NMR spectroscopy was employed to identify their structures. The drug's anti-malarial efficacy was assessed by estimating its growth-inhibitory activities employing the SYBR Green I asexual parasite drug assay. The cytotoxic effect was evaluated using the MTT assay. P. falciparum dihydroorotate dehydrogenase protein (Pf-DDP) was used as a drug target to investigate molecular docking. P. emblica crude extract and two fractions exhibited > 90% inhibition of 3D7 parasite proliferation, indicating good antimalarial activity at 100 and 10 µg/mL, respectively. Subsequently, the column chromatography study of each fraction, a targeted purification, contributed to the separation of six active compounds designated as 9-hydroxy isolongifolene (C1), Hexadecanoic acid (C2), Phenol, 2,6-Bis(1,1-Dimethylethyl) (C3), Furan, tetrahydro-3-methyl-4-methylene (C4), Octadecanoic acid (C5), and Beta-Sitosterol (C6). Compound C4 showed stronger bioactivity against P. falciparum (3D7) (IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.